Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs NRG Energy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.76 (market cap $39.89B), while NRG Energy Inc trades at $138.41 (market cap $29.63B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and NRG Energy Inc pays a 1.35% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NRG | |
|---|---|---|
Market Cap | $39.89B | $29.63B |
Sector | Health | Utilities |
52-Week High | $491.22 | $184.03 |
52-Week Low | $278.09 | $120.65 |
Enterprise Value | $38.15B | $53.46B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NRG Energy trades at $140.42, down 0.04% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong analyst support with 64% buy ratings, but faces high valuation with a P/E of 154.31 and modest net income margin of 0.74%. Recent earnings beat expectations in Q3 and Q4 2025, but missed in Q1 2026, with Q2 2026 results pending. Cash flow from operations was $1.91 billion in 2025, though debt levels have risen significantly.
Outlook is mixed: robust revenue growth and strategic initiatives like the smart home segment offer upside, but elevated debt and margin pressures pose risks. The stock's performance hinges on upcoming Q2 earnings and execution on EBITDA guidance of $5.325–$5.825 billion for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
